Quinolines attenuate PAF-induced pulmonary pressor responses and edema formation.
Identifieur interne : 000006 ( Ncbi/Curation ); précédent : 000005; suivant : 000007Quinolines attenuate PAF-induced pulmonary pressor responses and edema formation.
Auteurs : S. Falk [Allemagne] ; R. Göggel ; U. Heydasch ; F. Brasch ; K M Müller ; A. Wendel ; S. UhligSource :
- American journal of respiratory and critical care medicine [ 1073-449X ] ; 1999.
Descripteurs français
- KwdFr :
- Acide acétylsalicylique (pharmacologie), Acides gras insaturés, Animaux, Benzoquinones (pharmacologie), Chloroquine (pharmacologie), Circulation pulmonaire (), Composés hétérocycliques bicycliques, Facteur d'activation plaquettaire (physiologie), Facteur de nécrose tumorale alpha (métabolisme), Femelle, Hydrazines (pharmacologie), Inhibiteurs de la lipoxygénase (pharmacologie), Inhibiteurs des cyclooxygénases (pharmacologie), Interleukine-6 (métabolisme), Mâle, Oedème pulmonaire (), Oedème pulmonaire (métabolisme), Oedème pulmonaire (physiopathologie), Perméabilité capillaire, Poumon (), Poumon (métabolisme), Quinidine (pharmacologie), Quinine (pharmacologie), Quinoléines (pharmacologie), Rat Wistar, Rats, Récepteur thromboxane (antagonistes et inhibiteurs), Résistance des voies aériennes, Résistance vasculaire, Souris, Souris de lignée BALB C, Techniques in vitro, Vasoconstriction ().
- MESH :
- antagonistes et inhibiteurs : Récepteur thromboxane.
- métabolisme : Facteur de nécrose tumorale alpha, Interleukine-6, Oedème pulmonaire, Poumon.
- pharmacologie : Acide acétylsalicylique, Benzoquinones, Chloroquine, Hydrazines, Inhibiteurs de la lipoxygénase, Inhibiteurs des cyclooxygénases, Quinidine, Quinine, Quinoléines.
- physiologie : Facteur d'activation plaquettaire.
- physiopathologie : Oedème pulmonaire.
- Acides gras insaturés, Animaux, Circulation pulmonaire, Composés hétérocycliques bicycliques, Femelle, Mâle, Oedème pulmonaire, Perméabilité capillaire, Poumon, Rat Wistar, Rats, Résistance des voies aériennes, Résistance vasculaire, Souris, Souris de lignée BALB C, Techniques in vitro, Vasoconstriction.
English descriptors
- KwdEn :
- Airway Resistance, Animals, Aspirin (pharmacology), Benzoquinones (pharmacology), Bridged Bicyclo Compounds, Heterocyclic, Capillary Permeability, Chloroquine (pharmacology), Cyclooxygenase Inhibitors (pharmacology), Fatty Acids, Unsaturated, Female, Hydrazines (pharmacology), In Vitro Techniques, Interleukin-6 (metabolism), Lipoxygenase Inhibitors (pharmacology), Lung (blood supply), Lung (metabolism), Male, Mice, Mice, Inbred BALB C, Platelet Activating Factor (physiology), Pulmonary Circulation (drug effects), Pulmonary Edema (chemically induced), Pulmonary Edema (metabolism), Pulmonary Edema (physiopathology), Quinidine (pharmacology), Quinine (pharmacology), Quinolines (pharmacology), Rats, Rats, Wistar, Receptors, Thromboxane (antagonists & inhibitors), Tumor Necrosis Factor-alpha (metabolism), Vascular Resistance, Vasoconstriction (drug effects).
- MESH :
- chemical , antagonists & inhibitors : Receptors, Thromboxane.
- chemical , metabolism : Interleukin-6, Tumor Necrosis Factor-alpha.
- chemical , pharmacology : Aspirin, Benzoquinones, Chloroquine, Cyclooxygenase Inhibitors, Hydrazines, Lipoxygenase Inhibitors, Quinidine, Quinine, Quinolines.
- blood supply : Lung.
- chemically induced : Pulmonary Edema.
- drug effects : Pulmonary Circulation, Vasoconstriction.
- metabolism : Lung, Pulmonary Edema.
- chemical , physiology : Platelet Activating Factor.
- physiopathology : Pulmonary Edema.
- Airway Resistance, Animals, Bridged Bicyclo Compounds, Heterocyclic, Capillary Permeability, Fatty Acids, Unsaturated, Female, In Vitro Techniques, Male, Mice, Mice, Inbred BALB C, Rats, Rats, Wistar, Vascular Resistance.
Abstract
In the present study we have investigated the mechanisms of pulmonary edema caused by platelet-activating factor (PAF) in isolated rat lungs as well as in mice in vivo. In blood-free perfused and ventilated rat lungs, PAF increased lung weight by 0.59 +/- 0.18 g. The cyclooxygenase inhibitor aspirin (500 microM) blocked this response by one-third, and the quinolines quinine (330 microM), quinidine (100 microM), and chloroquine (100 microM) by two-thirds. Lipoxygenase inhibition (10 microM AA861) alone or in combination with thromboxane receptor antagonism (10 microM SQ29548) had no effect on PAF-induced weight gain. In combination with aspirin, quinine or quinidine completely prevented PAF-induced weight gain and the concomitant increase of the capillary filtration coefficient (K(f,c)). Pretreatment with quinine in vivo prevented not only PAF-, but also endotoxin-induced edema formation as assessed by Evans Blue extravasation. In addition, in vivo quinine prevented the endotoxin-induced release of tumor neurosis factor (TNF). Furthermore, in perfused lungs quinine reduced the PAF-induced increases in airway and vascular resistance, as well as thromboxane release. These findings demonstrate the following anti-inflammatory properties of quinolines: reduction of thromboxane and TNF formation; reduction of PAF-induced vasoconstriction and bronchoconstriction; and attenuation of PAF- and lipopolysaccharide (LPS)-induced edema formation. We conclude that the PAF- induced edema consists of two separate mechanisms, one dependent on an unknown cyclooxygenase metabolite, the other one sensitive to quinolines.
DOI: 10.1164/ajrccm.160.5.9902033
PubMed: 10556149
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000487
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :000487
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000466
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000006
Links to Exploration step
pubmed:10556149Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Quinolines attenuate PAF-induced pulmonary pressor responses and edema formation.</title><author><name sortKey="Falk, S" sort="Falk, S" uniqKey="Falk S" first="S" last="Falk">S. Falk</name><affiliation wicri:level="4"><nlm:affiliation>Biochemical Pharmacology, University of Konstanz, Konstanz, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Biochemical Pharmacology, University of Konstanz, Konstanz</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Fribourg-en-Brisgau</region><settlement type="city">Constance (Allemagne)</settlement></placeName><orgName type="university">Université de Constance</orgName></affiliation></author><author><name sortKey="Goggel, R" sort="Goggel, R" uniqKey="Goggel R" first="R" last="Göggel">R. Göggel</name></author><author><name sortKey="Heydasch, U" sort="Heydasch, U" uniqKey="Heydasch U" first="U" last="Heydasch">U. Heydasch</name></author><author><name sortKey="Brasch, F" sort="Brasch, F" uniqKey="Brasch F" first="F" last="Brasch">F. Brasch</name></author><author><name sortKey="Muller, K M" sort="Muller, K M" uniqKey="Muller K" first="K M" last="Müller">K M Müller</name></author><author><name sortKey="Wendel, A" sort="Wendel, A" uniqKey="Wendel A" first="A" last="Wendel">A. Wendel</name></author><author><name sortKey="Uhlig, S" sort="Uhlig, S" uniqKey="Uhlig S" first="S" last="Uhlig">S. Uhlig</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1999">1999</date><idno type="RBID">pubmed:10556149</idno><idno type="pmid">10556149</idno><idno type="doi">10.1164/ajrccm.160.5.9902033</idno><idno type="wicri:Area/PubMed/Corpus">000487</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000487</idno><idno type="wicri:Area/PubMed/Curation">000487</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000487</idno><idno type="wicri:Area/PubMed/Checkpoint">000466</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000466</idno><idno type="wicri:Area/Ncbi/Merge">000006</idno><idno type="wicri:Area/Ncbi/Curation">000006</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Quinolines attenuate PAF-induced pulmonary pressor responses and edema formation.</title><author><name sortKey="Falk, S" sort="Falk, S" uniqKey="Falk S" first="S" last="Falk">S. Falk</name><affiliation wicri:level="4"><nlm:affiliation>Biochemical Pharmacology, University of Konstanz, Konstanz, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Biochemical Pharmacology, University of Konstanz, Konstanz</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Fribourg-en-Brisgau</region><settlement type="city">Constance (Allemagne)</settlement></placeName><orgName type="university">Université de Constance</orgName></affiliation></author><author><name sortKey="Goggel, R" sort="Goggel, R" uniqKey="Goggel R" first="R" last="Göggel">R. Göggel</name></author><author><name sortKey="Heydasch, U" sort="Heydasch, U" uniqKey="Heydasch U" first="U" last="Heydasch">U. Heydasch</name></author><author><name sortKey="Brasch, F" sort="Brasch, F" uniqKey="Brasch F" first="F" last="Brasch">F. Brasch</name></author><author><name sortKey="Muller, K M" sort="Muller, K M" uniqKey="Muller K" first="K M" last="Müller">K M Müller</name></author><author><name sortKey="Wendel, A" sort="Wendel, A" uniqKey="Wendel A" first="A" last="Wendel">A. Wendel</name></author><author><name sortKey="Uhlig, S" sort="Uhlig, S" uniqKey="Uhlig S" first="S" last="Uhlig">S. Uhlig</name></author></analytic><series><title level="j">American journal of respiratory and critical care medicine</title><idno type="ISSN">1073-449X</idno><imprint><date when="1999" type="published">1999</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Airway Resistance</term><term>Animals</term><term>Aspirin (pharmacology)</term><term>Benzoquinones (pharmacology)</term><term>Bridged Bicyclo Compounds, Heterocyclic</term><term>Capillary Permeability</term><term>Chloroquine (pharmacology)</term><term>Cyclooxygenase Inhibitors (pharmacology)</term><term>Fatty Acids, Unsaturated</term><term>Female</term><term>Hydrazines (pharmacology)</term><term>In Vitro Techniques</term><term>Interleukin-6 (metabolism)</term><term>Lipoxygenase Inhibitors (pharmacology)</term><term>Lung (blood supply)</term><term>Lung (metabolism)</term><term>Male</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Platelet Activating Factor (physiology)</term><term>Pulmonary Circulation (drug effects)</term><term>Pulmonary Edema (chemically induced)</term><term>Pulmonary Edema (metabolism)</term><term>Pulmonary Edema (physiopathology)</term><term>Quinidine (pharmacology)</term><term>Quinine (pharmacology)</term><term>Quinolines (pharmacology)</term><term>Rats</term><term>Rats, Wistar</term><term>Receptors, Thromboxane (antagonists & inhibitors)</term><term>Tumor Necrosis Factor-alpha (metabolism)</term><term>Vascular Resistance</term><term>Vasoconstriction (drug effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Acide acétylsalicylique (pharmacologie)</term><term>Acides gras insaturés</term><term>Animaux</term><term>Benzoquinones (pharmacologie)</term><term>Chloroquine (pharmacologie)</term><term>Circulation pulmonaire ()</term><term>Composés hétérocycliques bicycliques</term><term>Facteur d'activation plaquettaire (physiologie)</term><term>Facteur de nécrose tumorale alpha (métabolisme)</term><term>Femelle</term><term>Hydrazines (pharmacologie)</term><term>Inhibiteurs de la lipoxygénase (pharmacologie)</term><term>Inhibiteurs des cyclooxygénases (pharmacologie)</term><term>Interleukine-6 (métabolisme)</term><term>Mâle</term><term>Oedème pulmonaire ()</term><term>Oedème pulmonaire (métabolisme)</term><term>Oedème pulmonaire (physiopathologie)</term><term>Perméabilité capillaire</term><term>Poumon ()</term><term>Poumon (métabolisme)</term><term>Quinidine (pharmacologie)</term><term>Quinine (pharmacologie)</term><term>Quinoléines (pharmacologie)</term><term>Rat Wistar</term><term>Rats</term><term>Récepteur thromboxane (antagonistes et inhibiteurs)</term><term>Résistance des voies aériennes</term><term>Résistance vasculaire</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Techniques in vitro</term><term>Vasoconstriction ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Receptors, Thromboxane</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Interleukin-6</term><term>Tumor Necrosis Factor-alpha</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Aspirin</term><term>Benzoquinones</term><term>Chloroquine</term><term>Cyclooxygenase Inhibitors</term><term>Hydrazines</term><term>Lipoxygenase Inhibitors</term><term>Quinidine</term><term>Quinine</term><term>Quinolines</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Récepteur thromboxane</term></keywords><keywords scheme="MESH" qualifier="blood supply" xml:lang="en"><term>Lung</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Pulmonary Edema</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Pulmonary Circulation</term><term>Vasoconstriction</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Lung</term><term>Pulmonary Edema</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Facteur de nécrose tumorale alpha</term><term>Interleukine-6</term><term>Oedème pulmonaire</term><term>Poumon</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Acide acétylsalicylique</term><term>Benzoquinones</term><term>Chloroquine</term><term>Hydrazines</term><term>Inhibiteurs de la lipoxygénase</term><term>Inhibiteurs des cyclooxygénases</term><term>Quinidine</term><term>Quinine</term><term>Quinoléines</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Facteur d'activation plaquettaire</term></keywords><keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Platelet Activating Factor</term></keywords><keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Oedème pulmonaire</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Pulmonary Edema</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Airway Resistance</term><term>Animals</term><term>Bridged Bicyclo Compounds, Heterocyclic</term><term>Capillary Permeability</term><term>Fatty Acids, Unsaturated</term><term>Female</term><term>In Vitro Techniques</term><term>Male</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Rats</term><term>Rats, Wistar</term><term>Vascular Resistance</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Acides gras insaturés</term><term>Animaux</term><term>Circulation pulmonaire</term><term>Composés hétérocycliques bicycliques</term><term>Femelle</term><term>Mâle</term><term>Oedème pulmonaire</term><term>Perméabilité capillaire</term><term>Poumon</term><term>Rat Wistar</term><term>Rats</term><term>Résistance des voies aériennes</term><term>Résistance vasculaire</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Techniques in vitro</term><term>Vasoconstriction</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In the present study we have investigated the mechanisms of pulmonary edema caused by platelet-activating factor (PAF) in isolated rat lungs as well as in mice in vivo. In blood-free perfused and ventilated rat lungs, PAF increased lung weight by 0.59 +/- 0.18 g. The cyclooxygenase inhibitor aspirin (500 microM) blocked this response by one-third, and the quinolines quinine (330 microM), quinidine (100 microM), and chloroquine (100 microM) by two-thirds. Lipoxygenase inhibition (10 microM AA861) alone or in combination with thromboxane receptor antagonism (10 microM SQ29548) had no effect on PAF-induced weight gain. In combination with aspirin, quinine or quinidine completely prevented PAF-induced weight gain and the concomitant increase of the capillary filtration coefficient (K(f,c)). Pretreatment with quinine in vivo prevented not only PAF-, but also endotoxin-induced edema formation as assessed by Evans Blue extravasation. In addition, in vivo quinine prevented the endotoxin-induced release of tumor neurosis factor (TNF). Furthermore, in perfused lungs quinine reduced the PAF-induced increases in airway and vascular resistance, as well as thromboxane release. These findings demonstrate the following anti-inflammatory properties of quinolines: reduction of thromboxane and TNF formation; reduction of PAF-induced vasoconstriction and bronchoconstriction; and attenuation of PAF- and lipopolysaccharide (LPS)-induced edema formation. We conclude that the PAF- induced edema consists of two separate mechanisms, one dependent on an unknown cyclooxygenase metabolite, the other one sensitive to quinolines.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000006 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 000006 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:10556149
|texte= Quinolines attenuate PAF-induced pulmonary pressor responses and edema formation.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:10556149" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |